Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aseripide SCHEMBL29387471 | 1.00 | PTGS2 (0.36) | PTGS2RORCCCKBRIDO1CYP1A2 | |
| Aseripide SCHEMBL5274420 | 1.00 | PTGS2 (0.36) | PTGS2RORCCCKBRIDO1CYP1A2 | |
| Aseripide SCHEMBL4096803 | 1.00 | PTGS2 (0.36) | PTGS2RORCCCKBRIDO1CYP1A2 | |
| SCHEMBL8870912 | 0.95 | PTGS2 (0.36) | PTGS2RORCCCKBRIDO1CYP1A2 | |
| SCHEMBL8870781 | 0.93 | IDO1 (0.34) | RORCCCKBRIDO1CYP1A2CYP2C19 | |
| SCHEMBL8870811 | 0.93 | IDO1 (0.34) | RORCCCKBRIDO1CYP1A2CYP2C19 | |
| SCHEMBL8870784 | 0.93 | IDO1 (0.34) | RORCCCKBRIDO1CYP1A2CYP2C19 | |
| SCHEMBL8870373 | 0.92 | BACE1 (0.34) | RORC | |
| SCHEMBL8870107 | 0.90 | MEN1 (0.36) | PTGS2RORCCCKBRCYP1A2CYP2C19 | |
| SCHEMBL8870841 | 0.88 | CASR (0.36) | CCKBRCYP1A2CYP2C19CASRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592466-B2 | Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia | NEUROPILL, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8592466-B2 | Methods for treating conditions caused by higher-than-normal dopaminergic activity in basal ganglia | NEUROPILL, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120289556-A1 | Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia | NEUROPILL, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289556-A1 | Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia | NEUROPILL, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-8247438-B2 | Methods for treating schizophrenia | NEUROPILL, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247438-B2 | Methods for treating schizophrenia | NEUROPILL, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| WO-2009108785-A2 | METHOD FOR TREATING SCHIZOPHRENIA | ELKASHEF AHMED (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215840-A1 | METHODS FOR TREATING SCHIZOPHRENIA | NEUROPILL, INC (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215840-A1 | METHODS FOR TREATING SCHIZOPHRENIA | CHAT, SLC6A3, DBH | PTGS2 2624/4885RORC 1893/4885CCKBR 1254/4885 |
| US-20120289556-A1 | Methods for Treating Conditions Caused by Higher-Than-Normal Dopaminergic Activity In Basal Ganglia | SNCA, PARK7, PYGB | PTGS2 1761/4885RORC 1835/4885CCKBR 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.